Travere Therapeutics (NASDAQ:TVTX) is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here’s a quick overview of what investors should know before the release.
Analysts are estimating that Travere Therapeutics will report an earnings per share (EPS) of $-0.12.
The announcement from Travere Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It’s worth noting for new investors that guidance can be a key determinant of stock price movements.
Earnings Track Record
The company’s EPS beat by $0.20 in the last quarter, leading to a 1.88% increase in the share price on the following day.
Here’s a look at Travere Therapeutics’s past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.39 | -0.38 | -0.68 | -0.86 |
| EPS Actual | -0.19 | -0.47 | -0.46 | -0.65 |
| Price Change % | 2.0% | -7.000000000000001% | 0.0% | -3.0% |
Tracking Travere Therapeutics’s Stock Performance
Shares of Travere Therapeutics were trading at $15.96 as of August 04. Over the last 52-week period, shares are up 97.39%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analyst Observations about Travere Therapeutics
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Travere Therapeutics.
A total of 4 analyst ratings …